Explore Cardiac Toxicity with Human Pluripotent Stem Cell (hPSC)-derived cardiomyocyte.
Cardiovascular disease is the most common cause of death around the world, accounting for estimated death of 17.7 million (WHO, 2017). The disease is the result of combinations of various factors including genetic or physiological conditions, as well as adverse drug reactions. In fact, the cardiotoxicity is common causes of withdrawal of the newly developed drugs from the market.
Using the NEXEL’s novel hPSC-derived cardiomyocytes can show better prediction of human cardiotoxicity compared to the animal cell derived models. Therefore, using Cardiosight-S® can substitute costly animal models and enables pharmaceutical industry to test cardiotoxicity in a more affordable fashion.
NEXEL provides Cardiosight-P as a progenitor cell type which has differentiation potential into cardiomyocytes. Explore cardiac development with human pluripotent stem cell (hPSC)-derived cardiac progenitors.
Applications of Cardiosight-S®
Cardiosight-S® can be used for various applications as such:
1. Cardiotoxicity testing
2. Drug discovery
3. Electrophysiological and biochemical assay
NEXEL provides two different types of cryopreserved Cardiosight-S®, which are terminally differentiated into functional cardiomyocytes. Cardiosight-S® can be used in various types of cell culture plates. Enquire for any technical guidance or questions.
Each kit contains
1. Cardiosight-S® Media (CM-001, 50 ml) 2. Cardioosight-S® Supplement (CS-001, 500 µl) 3. User's Guide
|Quantity||≥ 2 × 106 Viable cells/Vial|
Each kit contains
1. Cardiosight-S® Media (CM-002, 100 ml) 2. Cardiosight-S® Supplement (CS-002, 1 ml) 3. User's Guide
|Quantity||≥ 5 × 106 Viable cells/Vial|